

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA: Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

No equality issues have been identified.
------------------------------------------

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
---------------------------------------------------------------------------------------------------------------------

Not applicable.
-----------------

3. Has any change to the draft scope been agreed to highlight potential equality issues?
------------------------------------------------------------------------------------------

Not applicable.
-----------------

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Not applicable.
-----------------

**Approved by Associate Director (name):** ...Janet Robertson.....

**Date:** 07 October 2015